Imunon (IMNN) Q1 2026 Earnings Call Summary
During Imunon's Q1 2026 earnings call, management provided updates on clinical trial progress and financial performance. Enrollment for the Phase III OVATION III trial is progressing as planned with a target of enrolling 80 patients by year-end 2027 out of 500 total. The company also highlighted positive data from its Phase II OVATION II study, showing an overall survival benefit of 14.7 months for the treatment plus standard care.
Tickers: $IMNN
Topics: biotech clinical trials pharma